Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance).

lung cancer randomized trial sublobar resection

Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 28 04 2023
revised: 13 06 2023
accepted: 04 07 2023
pubmed: 21 7 2023
medline: 21 7 2023
entrez: 20 7 2023
Statut: ppublish

Résumé

We have recently reported the primary results of CALGB 140503 (Alliance), a randomized trial in patients with peripheral cT1aN0 non-small cell lung cancer (American Joint Committee on Cancer seventh) treated with either lobar resection (LR) or sublobar resection (SLR). Here we report differences in disease-free survival (DFS), overall survival (OS) and lung cancer-specific survival (LCSS) between LR, segmental resection (SR), and wedge resection (WR). We also report differences between WR and SR in terms of surgical margins, rate of locoregional recurrence (LRR), and expiratory flow rate at 6 months postoperatively. Between June 2007 and March 2017, a total of 697 patients were randomized to LR (n = 357) or SLR (n = 340) stratified by clinical tumor size, histology, and smoking history. Ten patients were converted from SLR to LR, and 5 patients were converted from LR to SLR. Survival endpoints were estimated using the Kaplan-Maier estimator and tested by the stratified log-rank test. The Kruskal-Wallis test was used to compare margins and changes in forced expiratory volume in 1 second (FEV1) between groups, and the χ A total of 362 patients had LR, 131 had SR, and 204 had WR. Basic demographic and clinical and pathologic characteristics were similar in the 3 groups. Five-year DFS was 64.7% after LR (95% confidence interval [CI], 59.6%-70.1%), 63.8% after SR (95% CI, 55.6%-73.2%), and 62.5% after WR (95% CI, 55.8%-69.9%) (P = .888, log-rank test). Five-year OS was 78.7% after LR, 81.9% after SR, and 79.7% after WR (P = .873, log-rank test). Five-year LCSS was 86.8% after LR, 89.2% after SR, and 89.7% after WR (P = .903, log-rank test). LRR occurred in 12% after SR and in 14% after WR (P = .295). At 6 months postoperatively, the median reduction in % FEV1 was 5% after WR and 3% after SR (P = .930). In this large randomized trial, LR, SR, and WR were associated with similar survival outcomes. Although LRR was numerically higher after WR compared to SR, the difference was not statistically significant. There was no significant difference in the reduction of FEV1 between the SR and WR groups.

Sections du résumé

BACKGROUND BACKGROUND
We have recently reported the primary results of CALGB 140503 (Alliance), a randomized trial in patients with peripheral cT1aN0 non-small cell lung cancer (American Joint Committee on Cancer seventh) treated with either lobar resection (LR) or sublobar resection (SLR). Here we report differences in disease-free survival (DFS), overall survival (OS) and lung cancer-specific survival (LCSS) between LR, segmental resection (SR), and wedge resection (WR). We also report differences between WR and SR in terms of surgical margins, rate of locoregional recurrence (LRR), and expiratory flow rate at 6 months postoperatively.
METHODS METHODS
Between June 2007 and March 2017, a total of 697 patients were randomized to LR (n = 357) or SLR (n = 340) stratified by clinical tumor size, histology, and smoking history. Ten patients were converted from SLR to LR, and 5 patients were converted from LR to SLR. Survival endpoints were estimated using the Kaplan-Maier estimator and tested by the stratified log-rank test. The Kruskal-Wallis test was used to compare margins and changes in forced expiratory volume in 1 second (FEV1) between groups, and the χ
RESULTS RESULTS
A total of 362 patients had LR, 131 had SR, and 204 had WR. Basic demographic and clinical and pathologic characteristics were similar in the 3 groups. Five-year DFS was 64.7% after LR (95% confidence interval [CI], 59.6%-70.1%), 63.8% after SR (95% CI, 55.6%-73.2%), and 62.5% after WR (95% CI, 55.8%-69.9%) (P = .888, log-rank test). Five-year OS was 78.7% after LR, 81.9% after SR, and 79.7% after WR (P = .873, log-rank test). Five-year LCSS was 86.8% after LR, 89.2% after SR, and 89.7% after WR (P = .903, log-rank test). LRR occurred in 12% after SR and in 14% after WR (P = .295). At 6 months postoperatively, the median reduction in % FEV1 was 5% after WR and 3% after SR (P = .930).
CONCLUSIONS CONCLUSIONS
In this large randomized trial, LR, SR, and WR were associated with similar survival outcomes. Although LRR was numerically higher after WR compared to SR, the difference was not statistically significant. There was no significant difference in the reduction of FEV1 between the SR and WR groups.

Identifiants

pubmed: 37473998
pii: S0022-5223(23)00612-8
doi: 10.1016/j.jtcvs.2023.07.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

338-347.e1

Subventions

Organisme : NCI NIH HHS
ID : UG1 CA233290
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233184
Pays : United States

Informations de copyright

Copyright © 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Nasser Altorki (N)

Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY. Electronic address: nkaltork@med.cornell.edu.

Xiaofei Wang (X)

Alliance Statistics and Data Management Center and Biostatistics and Bioinformatics, Duke University, Durham, NC.

Bryce Damman (B)

Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minn.

Jennifer Mentlick (J)

Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minn.

Rodney Landreneau (R)

University of Pittsburgh Medical Center, Pittsburgh, Pa.

Dennis Wigle (D)

Mayo Clinic, Rochester, Minn.

David R Jones (DR)

Memorial Sloan Kettering Cancer Center, New York, NY.

Massimo Conti (M)

Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Quebec, Canada.

Ahmad S Ashrafi (AS)

Surrey Memorial Hospital Thoracic Group, Fraser Valley Health Authority, Surrey, British Columbia, Canada.

Moishe Liberman (M)

Centre Hospitalier de Université de Montréal, Montreal, Quebec, Canada.

Marc de Perrot (M)

University of Toronto, Toronto, Ontario, Canada.

John D Mitchell (JD)

University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colo.

Robert Keenan (R)

Moffitt Cancer Center, Tampa, Fla.

Thomas Bauer (T)

Hackensack Meridian Health Center, Hackensack, NJ.

Daniel Miller (D)

Emory University School of Medicine, Atlanta, Ga.

Thomas E Stinchcombe (TE)

Duke Cancer Institute, Duke University Medical Center, Durham, NC.

Classifications MeSH